Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation on Glycaemic Control and Weight Change of Once Daily Levemir (Insulin Detemir) in Type 2 Diabetes Mellitus Treated by an Intensive Insulin Treatment (ICT).

Trial Profile

Evaluation on Glycaemic Control and Weight Change of Once Daily Levemir (Insulin Detemir) in Type 2 Diabetes Mellitus Treated by an Intensive Insulin Treatment (ICT).

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LEONCET2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 May 2009 Actual patient number (2289) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top